[Effect of bestatin on immuno-suppressive acidic protein in patients with stomach cancer].
Serum immuno-suppressive acidic protein (IAP) levels increased with the invasion of cancer in to the gastric wall, the progress of lymph nodes metastasis, and also with the increase of tumor diameter of the gastric mucosa. The immunopotentiator, Bestatin was administered for 7 days to 28 patients with gastric cancer before any other therapeutic treatment. high IAP levels (over 500 micrograms/ml) in patients with stage IV cancer were remarkably improved with this treatment.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000097:blood*; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
D000276:Adjuvants, Immunologic; D009363:Neoplasm Proteins; C030193:immunosuppressive acidic protein; D007930:Leucine; C012211:ubenimex